Zenith Drugs

{
  "main_header": {
    "sid": 10039174,
    "name": "Zenith Drugs",
    "stock_name": "Zenith Drugs",
    "full_name": "Zenith Drugs Ltd",
    "name_url": "stocks-analysis/zenith-drugs",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "49.00",
    "chg": -0.05,
    "chgp": "-0.1%",
    "dir": -1,
    "prev_price": "49.05",
    "mcapval": "81.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "ZENITHDRUG",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0QWN01013",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": 4800,
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/zenith-drugs-10039174-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Zenith Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-zenith-drugs-overvalued-or-undervalued-3713706",
        "imagepath": "",
        "date": "2025-11-19 08:11:30",
        "description": "As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued...."
      },
      {
        "title": "How has been the historical performance of Zenith Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-zenith-drugs-3704307",
        "imagepath": "",
        "date": "2025-11-15 00:33:05",
        "description": "Answer:\nThe historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability.\n\nBreakdown:\nZenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, f..."
      }
    ],
    "total": 102,
    "sid": "10039174",
    "stock_news_url": "https://www.marketsmojo.com/news/zenith-drugs-10039174"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Zenith Drugs Ltd has declared <strong>5%</strong> dividend, ex-date: 17 Sep 24",
          "dt": "2024-09-17",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Zenith Drugs overvalued or undervalued?

2025-11-19 08:11:30

As of 18 November 2025, Zenith Drugs has moved from a fair to an expensive valuation grade. The company appears to be overvalued at its current price of 57.35, especially when considering its PE ratio of 13.74, EV to EBIT of 14.11, and ROE of 9.98%. These metrics indicate that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Zenith Drugs' PE ratio is significantly lower than that of Sun Pharma (36.56) and Divi's Lab (69.17), which are both categorized as expensive to very expensive. Meanwhile, Cipla (22.49) and Dr. Reddy's Labs (17.97), which are rated attractive, have more favorable valuations. Additionally, Zenith Drugs has underperformed the Sensex significantly over the past year, with a stock return of -39.05% compared to the Sensex's 10.47%, reinforcing the notion that the stock is currently overvalued....

Read full news article

How has been the historical performance of Zenith Drugs?

2025-11-15 00:33:05

Answer: The historical performance of Zenith Drugs shows significant growth over the past three years, particularly in revenue and profitability. Breakdown: Zenith Drugs has experienced a steady increase in net sales, rising from 91.66 Cr in March 2022 to 114.52 Cr in March 2023, and further to 131.62 Cr in March 2024. Total operating income has mirrored this trend, reaching 131.62 Cr in March 2024. The company's total expenditure has also increased, from 84.82 Cr in March 2022 to 114.71 Cr in March 2024. However, operating profit (PBDIT) has shown a remarkable improvement, climbing from 7.85 Cr in March 2022 to 19.03 Cr in March 2024, indicating enhanced operational efficiency. Profit before tax has similarly surged from 4.41 Cr in March 2022 to 14.74 Cr in March 2024, while profit after tax has increased from 3.13 Cr to 10.94 Cr over the same period. The company's total assets have grown significantly, f...

Read full news article

View All News